Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study
暂无分享,去创建一个
Samuel Leung | C Blake Gilks | David G Huntsman | S. Leung | D. Huntsman | M. Köbel | S. Kalloger | C. Gilks | Robin L Parker | J. Arseneau | Steve E Kalloger | M. Duggan | Martin Köbel | Máire A Duggan | C. Ewanowich | Robin Parker | Patricia M Baker | Carol A Ewanowich | Jocelyne Arseneau | Viktor Zherebitskiy | Soran Abdulkarim | Dan Fontaine | P. Baker | D. Fontaine | Viktor A. Zherebitskiy | Soran Abdulkarim
[1] M. Duggan,et al. Pathology reviews in the research context: future directions. , 2010, Surgery.
[2] D. Huntsman,et al. Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[3] A. Mes-Masson,et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma , 2010, The Journal of pathology.
[4] D. Huntsman,et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. , 2010, Gynecologic oncology.
[5] Anna Adamiak,et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy , 2009, BMC Cancer.
[6] C. Gilks,et al. Ovarian carcinoma pathology and genetics: recent advances. , 2009, Human pathology.
[7] D. Huntsman,et al. A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary , 2009, The American journal of surgical pathology.
[8] A. Parwani. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma , 2009 .
[9] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[10] I. Shih,et al. Subdividing Ovarian and Peritoneal Serous Carcinoma Into Moderately Differentiated and Poorly Differentiated Does not Have Biologic Validity Based on Molecular Genetic and In Vitro Drug Resistance Data , 2008, The American journal of surgical pathology.
[11] D. Huntsman,et al. Critical molecular abnormalities in high-grade serous carcinoma of the ovary , 2008, Expert Reviews in Molecular Medicine.
[12] S. Leung,et al. Mixed Ovarian Epithelial Carcinomas With Clear Cell and Serous Components are Variants of High-grade Serous Carcinoma: An Interobserver Correlative and Immunohistochemical Study of 32 Cases , 2008, The American journal of surgical pathology.
[13] R. Soslow,et al. Histologic subtypes of ovarian carcinoma: an overview. , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[14] Ie-Ming Shih,et al. Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[15] P. Spellman,et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.
[16] K. Ogawa,et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. , 2007, Gynecologic oncology.
[17] W. McCluggage,et al. My approach to and thoughts on the typing of ovarian carcinomas , 2007, Journal of Clinical Pathology.
[18] Mark F. Munsell,et al. Interobserver and Intraobserver Variability of a Two-tier System for Grading Ovarian Serous Carcinoma , 2007, The American journal of surgical pathology.
[19] Jane Fountain,et al. Summary and discussion of session recommendations. , 2006, Gynecologic oncology.
[20] S. Hauptmann,et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas , 2006, Modern Pathology.
[21] L. Cope,et al. Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.
[22] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.
[23] Michael T Deavers,et al. Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.
[24] W. McCluggage,et al. WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma , 2004, Histopathology.
[25] I. Shih,et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.
[26] I. Jacobs,et al. Histopathologic Features of Genetically Determined Ovarian Cancer , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[27] Kathleen R. Cho,et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.
[28] I. Shih,et al. Diverse tumorigenic pathways in ovarian serous carcinoma. , 2002, The American journal of pathology.
[29] S. Tsugane,et al. Observer disagreement in histological classification of ovarian tumors in Japan. , 1994, Gynecologic oncology.
[30] B. Lund,et al. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications , 1991, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[31] H. Stalsberg,et al. Observer variation in histologic classification of malignant and borderline ovarian tumors. , 1988, Human pathology.
[32] T. Ulbright,et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. , 1987, Archives of pathology & laboratory medicine.
[33] T. Parmley,et al. Interobserver variability in the interpretation of epithelial ovarian cancer. , 1984, Gynecologic oncology.